DeepMed Research

Rogel Cancer Center: University of Michigan

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1991-01-01

Employees: -

Market Cap: -

Website: http://www.rogelcancercenter.org

Clinical Trials

Reduced-intensity Therapy for Oropharyngeal Cancer in Non-smoking HPV-16 Positive Patients

Not Applicable

Completed

Conditions: Squamous Cell Carcinoma of the Oropharynx
HPV

Interventions: Drug: Cetuximab
Radiation: Radiotherapy

First Posted Date: 2012-08-13

Last Posted Date: 2021-01-19

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 43

Registration Number: NCT01663259

Locations: 🇺🇸
Radiation Oncology , University of Michigan Health System, Ann Arbor, Michigan, United States

A Study of Neoadjuvant FOLFIRINOX and FDR-Gemcitabine With Concurrent IMRT in Patients

Phase 2

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: FOLFIRINOX
Radiation: Intensity-modulated radiotherapy (IMRT)
Procedure: Surgical Exploration

First Posted Date: 2012-08-09

Last Posted Date: 2019-11-13

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 25

Registration Number: NCT01661088

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers

Phase 2

Completed

Conditions: Pancreatic Cancer
Biliary Cancer

Interventions: Drug: Gemcitabine
Drug: 5-FU
Drug: Cisplatin

First Posted Date: 2012-08-09

Last Posted Date: 2016-10-19

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 39

Registration Number: NCT01661114

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

A Study Using Cone Beam CT for Head and Neck Cancer

Not Applicable

Completed

Conditions: Head and Neck Cancer

Interventions: Other: Cone Beam Computed Tomography (CT) Scan

First Posted Date: 2012-08-09

Last Posted Date: 2016-08-29

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 23

Registration Number: NCT01661062

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer

Phase 1

Terminated

Conditions: Prostate Cancer

Interventions: Other: Everolimus, lupron, bicalutamide, and radiation

First Posted Date: 2012-07-17

Last Posted Date: 2017-05-30

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 1

Registration Number: NCT01642732

Locations: 🇺🇸
Georgetown University, Washington, D.C., District of Columbia, United States
🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer

Phase 2

Completed

Conditions: Laryngeal Cancer

Interventions: Drug: AT-101
Drug: Docetaxel
Drug: Cisplatin
Drug: Carboplatin

First Posted Date: 2012-07-04

Last Posted Date: 2023-07-20

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 55

Registration Number: NCT01633541

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

Evaluation of Metformin, Targeting Cancer Stem Cells for Prevention of Relapse in Gynecologic Patients

Phase 2

Completed

Conditions: Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Interventions: Drug: Metformin

First Posted Date: 2012-04-18

Last Posted Date: 2018-05-25

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 90

Registration Number: NCT01579812

Locations: 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States

Safety & Efficacy of Lamivudine & Tenofovir to Lower Plasma Level of Viral RNA in Lymphoma

Phase 1

Withdrawn

Conditions: Lymphoma

Interventions: Drug: Lamivudine
Drug: Tenofovir disoproxil fumarate

First Posted Date: 2012-02-08

Last Posted Date: 2016-03-11

Lead Sponsor: University of Michigan Rogel Cancer Center

Registration Number: NCT01528865

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

A Study of Individualized Stereotactic Body Radiation Therapy (SBRT) for Intrahepatic Cancer

Phase 2

Completed

Conditions: Liver Cancer
Hepatocellular Cancer

Interventions: Radiation: individualized Stereotactic Body Radiation Therapy (SBRT)

First Posted Date: 2012-02-01

Last Posted Date: 2017-03-09

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 94

Registration Number: NCT01522937

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

Assessment Of Liver Function in Patients Undergoing Hepatic Irradiation

Completed

Conditions: Hepatic Irradiation

Interventions: Radiation: Hepatic Irradiation

First Posted Date: 2012-01-26

Last Posted Date: 2020-05-20

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 208

Registration Number: NCT01519219

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy